Harnessing the apoptotic programs in cancer stem-like cells

EMBO Reports

Volumn 16, Issue 9, 2015, Pages 1084-1098

  Wang, Ying Hua ^a,b,c   Scadden, David T ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD STEM CELL INSTITUTE   (United States)

^c Harvard University   (United States)

Author keywords

apoptosis; cancer stem cells; cancer therapy

Indexed keywords

DEATH RECEPTOR; PROTEIN BCL 2; PROTEIN P53; BCL2 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

APOPTOSIS; CANCER PROGNOSIS; CANCER STEM CELL; CANCER THERAPY; CARCINOGENICITY; CELL CYCLE CHECKPOINT; CELL METABOLISM; CELL POPULATION; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; DNA DAMAGE; DNA RESPONSIVE ELEMENT; ENERGY METABOLISM; GLIOBLASTOMA; GLIOMA STEM CELL; HUMAN; MESENCHYMAL STROMA CELL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; NEOPLASTIC STEM CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84940795027     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201439675     Document Type: Review

References (167)

1. Green DR, Reed JC, (1998) Mitochondria and apoptosis. Science 281: 1309-1312
2. Zhao J, Lu Y, Shen HM, (2012) Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Lett 314: 8-23
3. Duronio V, (2008) The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem J 415: 333-344
4. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674
5. Cotter TG, (2009) Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9: 501-507
6. Signore M, Ricci-Vitiani L, De Maria R, (2013) Targeting apoptosis pathways in cancer stem cells. Cancer Lett 332: 374-382
7. Bonnet D, Dick JE, (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730-737
8. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE, (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648
9. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768
10. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF, (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983-3988
11. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al, (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555-567
12. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R, (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115
13. O'Brien CA, Pollett A, Gallinger S, Dick JE, (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110
14. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, Hoey T, Gurney A, Huang EH, Simeone DM, et al, (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 104: 10158-10163
15. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM, (2009) Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 69: 3382-3389
16. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB, (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821-5828
17. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB, (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401
18. Mao XG, Zhang X, Xue XY, Guo G, Wang P, Zhang W, Fei Z, Zhen HN, You SW, Yang H, (2009) Brain tumor stem-like cells identified by neural stem cell marker CD15. Transl Oncol 2: 247-257
19. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, et al, (2008) Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer 18: 506-514
20. - ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clin Exp Metastasis 29: 939-948
21. Luo L, Zeng J, Liang B, Zhao Z, Sun L, Cao D, Yang J, Shen K, (2011) Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol 91: 596-602
22. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY, (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542-2556
23. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, et al, (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450
24. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al, (2009) EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136: 1012-1024
25. + cancer stem cells in human liver cancer. Cancer Cell 13: 153-166
26. Yang W, Yan HX, Chen L, Liu Q, He YQ, Yu LX, Zhang SH, Huang DD, Tang L, Kong XN, et al, (2008) Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 68: 4287-4295
27. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM, (2007) Identification of pancreatic cancer stem cells. Cancer Res 67: 1030-1037
28. Akunuru S, James Zhai Q, Zheng Y, (2012) Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis 3: e352
29. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, Ridler C, Lillington D, Oakervee H, Cavenagh J, Agrawal SG, et al, (2008) Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood 112: 568-575
30. Ishizawa K, Rasheed ZA, Karisch R, Wang Q, Kowalski J, Susky E, Pereira K, Karamboulas C, Moghal N, Rajeshkumar NV, et al, (2010) Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 7: 279-282
31. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ, (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593-598
32. Beck B, Blanpain C, (2013) Unravelling cancer stem cell potential. Nat Rev Cancer 13: 727-738
33. Morrison R, Schleicher SM, Sun Y, Niermann KJ, Kim S, Spratt DE, Chung CH, Lu B, (2011) Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011: 941876
34. - progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities. Cancer Res 60: 4403-4411
35. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y, Fontana A, (1994) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94: 954-964
36. Frei K, Ambar B, Adachi N, Yonekawa Y, Fontana A, (1998) Ex vivo malignant glioma cells are sensitive to Fas (CD95/APO-1) ligand-mediated apoptosis. J Neuroimmunol 87: 105-113
37. Tao J, Qiu B, Zhang D, Wang Y, (2012) Expression levels of Fas/Fas-L mRNA in human brain glioma stem cells. Mol Med Rep 5: 1202-1206
38. Eisele G, Roth P, Hasenbach K, Aulwurm S, Wolpert F, Tabatabai G, Wick W, Weller M, (2011) APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol 13: 155-164
39. Eisele G, Wolpert F, Decrey G, Weller M, (2013) APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells. Anticancer Res 33: 3563-3571
40. Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T, (2002) TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 16: 67-73
41. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, et al, (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821
42. Unterkircher T, Cristofanon S, Vellanki SH, Nonnenmacher L, Karpel-Massler G, Wirtz CR, Debatin KM, Fulda S, (2011) Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 17: 4019-4030
43. Yin S, Xu L, Bandyopadhyay S, Sethi S, Reddy KB, (2011) Cisplatin and TRAIL enhance breast cancer stem cell death. Int J Oncol 39: 891-898
44. Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L, Zhu J, (2009) Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells. Neurosurgery 65: 610-624; discussion 624
45. Menon LG, Kelly K, Yang HW, Kim SK, Black PM, Carroll RS, (2009) Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 27: 2320-2330
46. Ciavarella S, Grisendi G, Dominici M, Tucci M, Brunetti O, Dammacco F, Silvestris F, (2012) In vitro anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. Br J Haematol 157: 586-598
47. Reagan MR, Seib FP, McMillin DW, Sage EK, Mitsiades CS, Janes SM, Ghobrial IM, Kaplan DL, (2012) Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. J Breast Cancer 15: 273-282
48. Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ, Warnock GL, (2012) TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther 19: 652-658
49. Loebinger MR, Sage EK, Davies D, Janes SM, (2010) TRAIL-expressing mesenchymal stem cells kill the putative cancer stem cell population. Br J Cancer 103: 1692-1697
50. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz JD, Koopman WJ, Kimberly RP, et al, (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960
51. Kaliberov S, Stackhouse MA, Kaliberova L, Zhou T, Buchsbaum DJ, (2004) Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. Gene Ther 11: 658-667
52. Oliver PG, LoBuglio AF, Zinn KR, Kim H, Nan L, Zhou T, Wang W, Buchsbaum DJ, (2008) Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res 14: 2180-2189
53. Bonner JA, Willey CD, Yang ES, Dobelbower MC, Sanford LL, Bright SJ, Buchsbaum DJ, Raisch KP, (2011) Treatment of small cell lung cancer with TRA-8 in combination with cisplatin and radiation. Radiother Oncol 101: 183-189
54. Yada A, Yazawa M, Ishida S, Yoshida H, Ichikawa K, Kurakata S, Fujiwara K, (2008) A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 19: 1060-1067
55. Rajeshkumar NV, Rasheed ZA, Garcia-Garcia E, Lopez-Rios F, Fujiwara K, Matsui WH, Hidalgo M, (2010) A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model. Mol Cancer Ther 9: 2582-2592
56. Londono-Joshi AI, Oliver PG, Li Y, Lee CH, Forero-Torres A, LoBuglio AF, Buchsbaum DJ, (2011) Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. Breast Cancer Res Treat 133: 437-445
57. Sussman RT, Ricci MS, Hart LS, Sun SY, El-Deiry WS, (2007) Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol Ther 6: 1490-1495
58. Li M, Knight DA, Smyth MJ, Stewart TJ, (2012) Sensitivity of a novel model of mammary cancer stem cell-like cells to TNF-related death pathways. Cancer Immunol Immunother 61: 1255-1268
59. Dutton A, Young LS, Murray PG, (2006) The role of cellular FLICE inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Expert Opin Ther Targets 10: 27-35
60. Shirley S, Micheau O, (2013) Targeting c-FLIP in cancer. Cancer Lett 332: 141-150
61. Zobalova R, Stantic M, Prokopova K, Dong LF, Neuzil J, (2009) Cancer cells with high expression of CD133 exert FLIP upregulation and resistance to TRAIL-induced apoptosis. BioFactors 34: 231-235
62. Zobalova R, McDermott L, Stantic M, Prokopova K, Dong LF, Neuzil J, (2008) CD133-positive cells are resistant to TRAIL due to up-regulation of FLIP. Biochem Biophys Res Commun 373: 567-571
63. Ding L, Yuan C, Wei F, Wang G, Zhang J, Bellail AC, Zhang Z, Olson JJ, Hao C, (2011) Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest 29: 511-520
64. Piggott L, Omidvar N, Marti Perez S, Eberl M, Clarkson RW, (2011) Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL. Breast Cancer Res 13: R88
65. Llobet D, Eritja N, Yeramian A, Pallares J, Sorolla A, Domingo M, Santacana M, Gonzalez-Tallada FJ, Matias-Guiu X, Dolcet X, (2010) The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer 46: 836-850
66. Pennarun B, Kleibeuker JH, Boersma-van Ek W, Kruyt FA, Hollema H, de Vries EG, de Jong S, (2013) Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL. J Pathol 229: 410-421
67. Yoon MJ, Kang YJ, Kim IY, Kim EH, Lee JA, Lim JH, Kwon TK, Choi KS, (2013) Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation. Carcinogenesis 34: 1918-1928
68. Chen X, Wang T, Yang D, Wang J, Li X, He Z, Chen F, Che X, Song X, (2013) Expression of the IAP protein family acts cooperatively to predict prognosis in human bladder cancer patients. Oncol Lett 5: 1278-1284
69. Grzybowska-Izydorczyk O, Cebula B, Robak T, Smolewski P, (2010) Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia. Eur J Cancer 46: 800-810
70. Fulda S, Vucic D, (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11: 109-124
71. Wu TY, Wagner KW, Bursulaya B, Schultz PG, Deveraux QL, (2003) Development and characterization of nonpeptidic small molecule inhibitors of the XIAP/caspase-3 interaction. Chem Biol 10: 759-767
72. Schimmer AD, Welsh K, Pinilla C, Wang Z, Krajewska M, Bonneau MJ, Pedersen IM, Kitada S, Scott FL, Bailly-Maitre B, et al, (2004) Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 5: 25-35
73. Loeder S, Drensek A, Jeremias I, Debatin KM, Fulda S, (2010) Small molecule XIAP inhibitors sensitize childhood acute leukemia cells for CD95-induced apoptosis. Int J Cancer 126: 2216-2228
74. Checinska A, Hoogeland BS, Rodriguez JA, Giaccone G, Kruyt FA, (2007) Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation. Exp Cell Res 313: 1215-1224
75. Engesaeter BO, Sathermugathevan M, Hellenes T, Engebraten O, Holm R, Florenes VA, Maelandsmo GM, (2011) Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells. Cancer Biol Ther 12: 47-58
76. Vogler M, Walczak H, Stadel D, Haas TL, Genze F, Jovanovic M, Bhanot U, Hasel C, Moller P, Gschwend JE, et al, (2009) Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res 69: 2425-2434
77. Mohr A, Albarenque SM, Deedigan L, Yu R, Reidy M, Fulda S, Zwacka RM, (2010) Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells. Stem Cells 28: 2109-2120
78. + cancer stem cells in glioblastoma. Mol Cancer 5: 67
79. Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, Boeckers T, Debatin KM, Fulda S, (2009) Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 11: 743-752
80. Kahana S, Finniss S, Cazacu S, Xiang C, Lee HK, Brodie S, Goldstein RS, Roitman V, Slavin S, Mikkelsen T, et al, (2011) Proteasome inhibitors sensitize glioma cells and glioma stem cells to TRAIL-induced apoptosis by PKCepsilon-dependent downregulation of AKT and XIAP expressions. Cell Signal 23: 1348-1357
81. Tsujimoto Y, Cossman J, Jaffe E, Croce CM, (1985) Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1443
82. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM, (1985) The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 229: 1390-1393
83. Mandik L, Katsumata M, Erikson J, (1997) Effects of altered Bcl-2 expression on B lymphocyte selection. Ann N Y Acad Sci 815: 40-54
84. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ, (1991) BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88: 6961-6965
85. Domen J, Cheshier SH, Weissman IL, (2000) The role of apoptosis in the regulation of hematopoietic stem cells: overexpression of Bcl-2 increases both their number and repopulation potential. J Exp Med 191: 253-264
86. Domen J, Weissman IL, (2000) Hematopoietic stem cells need two signals to prevent apoptosis; BCL-2 can provide one of these, Kitl/c-Kit signaling the other. J Exp Med 192: 1707-1718
87. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ, (1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75: 229-240
88. Matsuzaki Y, Nakayama K, Nakayama K, Tomita T, Isoda M, Loh DY, Nakauchi H, (1997) Role of bcl-2 in the development of lymphoid cells from the hematopoietic stem cell. Blood 89: 853-862
89. Ma A, Pena JC, Chang B, Margosian E, Davidson L, Alt FW, Thompson CB, (1995) Bclx regulates the survival of double-positive thymocytes. Proc Natl Acad Sci USA 92: 4763-4767
90. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S, et al, (1995) Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science 267: 1506-1510
91. Motoyama N, Kimura T, Takahashi T, Watanabe T, Nakano T, (1999) bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation. J Exp Med 189: 1691-1698
92. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, Korsmeyer SJ, (2005) Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 307: 1101-1104
93. Huang HM, Huang CJ, Yen JJ, (2000) Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways. Blood 96: 1764-1771
94. Czabotar PE, Lessene G, Strasser A, Adams JM, (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15: 49-63
95. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al, (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905
96. Letai A, Sorcinelli MD, Beard C, Korsmeyer SJ, (2004) Antiapoptotic BCL-2 is required for maintenance of a model leukemia. Cancer Cell 6: 241-249
97. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U, (1997) Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89: 1027-1036
98. Yamanaka K, Rocchi P, Miyake H, Fazli L, Vessella B, Zangemeister-Wittke U, Gleave ME, (2005) A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells. Mol Cancer Ther 4: 1689-1698
99. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H, (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4: 232-234
100. Julien T, Frankel B, Longo S, Kyle M, Gibson S, Shillitoe E, Ryken T, (2000) Antisense-mediated inhibition of the bcl-2 gene induces apoptosis in human malignant glioma. Surg Neurol 53: 360-368; discussion 368-369
101. Kantarjian HM, Talpaz M, Santini V, Murgo A, Cheson B, O'Brien SM, (2001) Homoharringtonine: history, current research, and future direction. Cancer 92: 1591-1605
102. Chen Y, Hu Y, Michaels S, Segal D, Brown D, Li S, (2009) Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice. Leukemia 23: 1446-1454
103. Allan EK, Holyoake TL, Craig AR, Jorgensen HG, (2011) Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 25: 985-994
104. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, et al, (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681
105. Lauria F, Raspadori D, Rondelli D, Ventura MA, Fiacchini M, Visani G, Forconi F, Tura S, (1997) High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia 11: 2075-2078
106. Tothova E, Fricova M, Stecova N, Kafkova A, Elbertova A, (2002) High expression of Bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma 49: 141-144
107. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud JP, Guyotat D, (1993) High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091-3096
108. + cancer cells express higher levels of the anti-apoptotic protein Bcl-2 in breast tumours. Cancer Immun 9: 4
109. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC, Macher-Goeppinger S, Radlwimmer B, Wiestler OD, Herold-Mende C, et al, (2008) Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 27: 6646-6656
110. Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V, Kogel D, (2010) The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res 8: 1002-1016
111. Beverly LJ, Varmus HE, (2009) MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 28: 1274-1279
112. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, et al, (2005) Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105: 3303-3311
113. + progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 26: 788-794
114. Goff DJ, Recart AC, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, Leu H, Low-Marchelli J, Ma W, Shih AY, et al, (2013) A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell 12: 316-328
115. Lagadinou ED, Sach A, Callahan K, Rossi RM, Neering SJ, Minhajuddin M, Ashton JM, Pei S, Grose V, O'Dwyer KM, et al, (2013) BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 12: 329-341
116. Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, et al, (2013) BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells. Blood 122: 2864-2876
117. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A, (2012) Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151: 344-355
118. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314
119. Palorini R, Votta G, Balestrieri C, Monestiroli A, Olivieri S, Vento R, Chiaradonna F, (2013) Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS. J Cell Biochem 115: 368-379
120. Morfouace M, Lalier L, Bahut M, Bonnamain V, Naveilhan P, Guette C, Oliver L, Gueguen N, Reynier P, Vallette FM, (2012) Comparison of spheroids formed by rat glioma stem cells and neural stem cells reveals differences in glucose metabolism and promising therapeutic applications. J Biol Chem 287: 33664-33674
121. Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, Popescu R, Della Donna L, Evers P, Dekmezian C, et al, (2011) Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci USA 108: 16062-16067
122. Janiszewska M, Suva ML, Riggi N, Houtkooper RH, Auwerx J, Clement-Schatlo V, Radovanovic I, Rheinbay E, Provero P, Stamenkovic I, (2012) Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev 26: 1926-1944
123. Alvero AB, Montagna MK, Holmberg JC, Craveiro V, Brown D, Mor G, (2011) Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther 10: 1385-1393
124. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, et al, (2010) Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 120: 142-156
125. Ito K, Carracedo A, Weiss D, Arai F, Ala U, Avigan DE, Schafer ZT, Evans RM, Suda T, Lee CH, et al, (2012) A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med 18: 1350-1358
126. Ito K, Bernardi R, Morotti A, Matsuoka S, Saglio G, Ikeda Y, Rosenblatt J, Avigan DE, Teruya-Feldstein J, Pandolfi PP, (2008) PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453: 1072-1078
127. Sax JK, El-Deiry WS, (2003) p53 downstream targets and chemosensitivity. Cell Death Differ 10: 413-417
128. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A, (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221
129. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA, (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7
130. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, et al, (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708
131. Hollstein M, Sidransky D, Vogelstein B, Harris CC, (1991) p53 mutations in human cancers. Science 253: 49-53
132. Chen F, Wang W, El-Deiry WS, (2010) Current strategies to target p53 in cancer. Biochem Pharmacol 80: 724-730
133. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E, Xu Y, (2005) p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 7: 165-171
134. Meletis K, Wirta V, Hede SM, Nister M, Lundeberg J, Frisen J, (2006) p53 suppresses the self-renewal of adult neural stem cells. Development 133: 363-369
135. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S, et al, (2009) p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4: 37-48
136. Zhao Z, Zuber J, Diaz-Flores E, Lintault L, Kogan SC, Shannon K, Lowe SW, (2010) p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes Dev 24: 1389-1402
137. Spike BT, Wahl GM, (2011) p53, stem cells, and reprogramming: tumor suppression beyond guarding the genome. Genes Cancer 2: 404-419
138. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, Giulini B, Brisken C, Minucci S, Di Fiore PP, Pelicci PG, (2009) The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138: 1083-1095
139. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, Holyoake TL, Chen W, Bhatia R, (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21: 266-281
140. Huang C, Zhang XM, Tavaluc RT, Hart LS, Dicker DT, Wang W, El-Deiry WS, (2009) The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol Ther 8: 2186-2193
141. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al, (2011) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148: 244-258
142. Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera N, Josselin E, Finetti P, Guille A, Larderet G, Viens P, et al, (2012) Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. Stem Cells 30: 1327-1337
143. Hartwell KA, Miller PG, Mukherjee S, Kahn AR, Stewart AL, Logan DJ, Negri JM, Duvet M, Jaras M, Puram R, et al, (2013) Niche-based screening identifies small-molecule inhibitors of leukemia stem cells. Nat Chem Biol 9: 840-848
144. Liu P, Cheng H, Roberts TM, Zhao JJ, (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627-644
145. Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC, (2008) PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22: 436-448
146. Carra E, Barbieri F, Marubbi D, Pattarozzi A, Favoni RE, Florio T, Daga A, (2013) Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle 12: 491-500
147. Firat E, Weyerbrock A, Gaedicke S, Grosu AL, Niedermann G, (2012) Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote gamma-irradiation-induced cell death in primary stem-like glioma cells. PLoS ONE 7: e47357
148. Kanai R, Wakimoto H, Martuza RL, Rabkin SD, (2011) A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res 17: 3686-3696
149. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M, (2003) Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 102: 972-980
150. Xu Q, Thompson JE, Carroll M, (2005) mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 106: 4261-4268
151. Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, et al, (2012) mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 11: 429-439
152. Magee JA, Ikenoue T, Nakada D, Lee JY, Guan KL, Morrison SJ, (2012) Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression. Cell Stem Cell 11: 415-428
153. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, Nakao S, Motoyama N, Hirao A, (2010) TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463: 676-680
154. Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, et al, (2011) AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 146: 697-708
155. Ibanez E, Agliano A, Prior C, Nguewa P, Redrado M, Gonzalez-Zubeldia I, Plano D, Palop JA, Sanmartin C, Calvo A, (2012) The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity. Curr Med Chem 19: 3031-3043
156. Kumar D, Shankar S, Srivastava RK, (2013) Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway. Cancer Lett 343: 179-189
157. Liu H, Han D, Liu Y, Hou X, Wu J, Li H, Yang J, Shen C, Yang G, Fu C, et al, (2013) Harmine hydrochloride inhibits Akt phosphorylation and depletes the pool of cancer stem-like cells of glioblastoma. J Neurooncol 112: 39-48
158. Wang JY, Chang CC, Chiang CC, Chen WM, Hung SC, (2012) Silibinin suppresses the maintenance of colorectal cancer stem-like cells by inhibiting PP2A/AKT/mTOR pathways. J Cell Biochem 113: 1733-1743
159. Shimura T, Noma N, Oikawa T, Ochiai Y, Kakuda S, Kuwahara Y, Takai Y, Takahashi A, Fukumoto M, (2012) Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells. Oncogenesis 1: e12
160. Moore N, Lyle S, (2011) Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol doi: 10.1155/2011/396076
161. Leal JA, Lleonart ME, (2013) MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett 338: 174-183
162. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, Huang Y, Hu X, Su F, Lieberman J, et al, (2007) let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109-1123
163. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, Jacks T, (2008) Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci USA 105: 3903-3908
164. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ, (2008) The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 7: 759-764
165. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY, (2007) miR-21-mediated tumor growth. Oncogene 26: 2799-2803
166. Huynh C, Segura MF, Gaziel-Sovran A, Menendez S, Darvishian F, Chiriboga L, Levin B, Meruelo D, Osman I, Zavadil J, et al, (2011) Efficient in vivo microRNA targeting of liver metastasis. Oncogene 30: 1481-1488
167. Ji J, Yamashita T, Budhu A, Forgues M, Jia HL, Li C, Deng C, Wauthier E, Reid LM, Ye QH, et al, (2009) Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology 50: 472-480